2,310 research outputs found
Recommended from our members
Impact of meltwater on high-latitude early Last Interglacial climate
Recent data compilations of the early Last Interglacial period have indicated a bipolar temperature response at 130 ka, with colder-than-present temperatures in the North Atlantic and warmer-than-present temperatures in the Southern Ocean and over Antarctica. However, climate model simulations of this period have been unable to reproduce this response, when only orbital and greenhouse gas forcings are considered in a climate model framework. Using a full-complexity general circulation model we perform climate model simulations representative of 130 ka conditions which include a magnitude of freshwater forcing derived from data at this time. We show that this meltwater from the remnant Northern Hemisphere ice sheets during the glacial-interglacial transition produces a modelled climate response similar to the observed colder-than-present temperatures in the North Atlantic at 130 ka and also results in warmer-than-present temperatures in the Southern Ocean via the bipolar seesaw mechanism. Further simulations in which the West Antarctic Ice Sheet is also removed lead to warming in East Antarctica and the Southern Ocean but do not appreciably improve the model-data comparison. This integrated model-data approach provides evidence that Northern Hemisphere freshwater forcing is an important player in the evolution of early Last Interglacial climate.This work was carried out with funding from the UK-NERC consortium iGlass (NE/I009906/1) and is also a contribution to the European Union’s Seventh Framework programme (FP7/2007–2013) under grant agreement 243908, “Past4Future. Climate change – Learning from the past climate”. This is Past4Future contribution no. 85
Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level.
Acetazolamide is the standard carbonic anhydrase (CA) inhibitor used for acute mountain sickness (AMS), however some of its undesirable effects are related to intracellular penetrance into many tissues, including across the blood-brain barrier. Benzolamide is a much more hydrophilic inhibitor, which nonetheless retains a strong renal action to engender a metabolic acidosis and ventilatory stimulus that improves oxygenation at high altitude and reduces AMS. We tested the effectiveness of benzolamide versus placebo in a first field study of the drug as prophylaxis for AMS during an ascent to the Everest Base Camp (5340 m). In two other studies performed at sea level to test side effect differences between acetazolamide and benzolamide, we assessed physiological actions and psychomotor side effects of two doses of acetazolamide (250 and 1000 mg) in one group of healthy subjects and in another group compared acetazolamide (500 mg), benzolamide (200 mg) and lorazepam (2 mg) as an active comparator for central nervous system (CNS) effects. At high altitude, benzolamide-treated subjects maintained better arterial oxygenation at all altitudes (3-6% higher at all altitudes above 4200 m) than placebo-treated subjects and reduced AMS severity by roughly 50%. We found benzolamide had fewer side effects, some of which are symptoms of AMS, than any of the acetazolamide doses in Studies 1 and 2, but equal physiological effects on renal function. The psychomotor side effects of acetazolamide were dose dependent. We conclude that benzolamide is very effective for AMS prophylaxis. With its lesser CNS effects, benzolamide may be superior to acetazolamide, in part, because some of the side effects of acetazolamide may contribute to and be mistaken for AMS
Normal hindfoot alignment assessed by weight bearing CT : presence of a constitutional valgus?
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
PMCID: PMC3446380This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
<p>Abstract</p> <p>Background</p> <p>In August 2002, the antifungal prophylaxis algorithm for neutropenic hematology/oncology (NHO) patients at the Medical Center was changed from conventional amphotericin (AMB) to an azole (AZ) based regimen (fluconazole [FLU] in low-risk and voriconazole [VOR] in high-risk patients). The aim of our study was to compare outcomes associated with the two regimens, including breakthrough fungal infection, adverse drug events, and costs.</p> <p>Methods</p> <p>Adult, non-febrile, NHO patients who received prophylactic AMB from 8/01/01-7/30/02 or AZ from 8/01/02-7/30/03 were retrospectively evaluated.</p> <p>Results</p> <p>A total of 370 patients (AMB: n = 181; AZ: n = 216) associated with 580 hospitalizations (AMB: n = 259; AZ: n = 321) were included. The incidence of probable/definite breakthrough Aspergillus infections was similar among regimens (AMB: 1.9% vs AZ: 0.6%; p=0.19). A greater incidence of mild/moderate (24.7% vs. 5.3%; p < 0.0001) and severe renal dysfunction (13.5% vs. 4.4%; p < 0.0012) was observed with AMB. In contrast, patients treated with VOR were found to have an increased rate of severe hepatic toxicity (32.5%) compared with patients treated with either AMB (22.6%) or FLU (21.4%) (p = 0.05). While the AZ period was associated with a >947/hospitalization more than AMB.</p> <p>Conclusion</p> <p>While an AZ-based regimen is associated with increased cost, the reduced rate of nephrotoxicity and availability of oral dosage forms, suggests that azoles be used preferentially over AMB. However, an increased rate of severe hepatic toxicity may be associated with VOR.</p
- …